GlassScriptPhysician profile
Tiffany A Replogle
NPI 1871569467
$4,180.02
in general payments reported to CMS, 2019-2025
24 companies · $1,441 in 2025
The $1,441 reported for 2025 was more than what 86% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $18.43 · 2022: $600 · 2023: $823 · 2024: $1,298 · 2025: $1,441.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,438 · Education: $123.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,438.41 |
| Education | $123.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $740.53 | 2022-2025 | Tremfya, Simponi Aria, Stelara |
| Abbvie INC. | $517.28 | 2022-2025 | |
| Ucb, INC. | $516.24 | 2022-2025 | Bimzelx, Cimzia |
| Novartis Pharmaceuticals Corporation | $423.77 | 2022-2025 | |
| Genzyme Corporation | $374.39 | 2022-2025 | |
| Amgen INC. | $240.27 | 2022-2025 | Otezla, Otezla |
| Regeneron Healthcare Solutions, INC. | $172.26 | 2023-2025 | Dupixent, Libtayo |
| Lilly USA, LLC | $147.38 | 2022-2025 | Ebglyss, Taltz, Olumiant |
| Sun Pharmaceutical Industries INC. | $132.84 | 2022-2024 | Winlevi, Blu-U, Odomzo |
| Incyte Corporation | $123.34 | 2022-2025 | Opzelura |
| Organogenesis INC. | $116.79 | 2022-2025 | Puraply, Puraply Am, Puraply Wound Matrix |
| Biofrontera INC. | $107.08 | 2021-2025 | Ameluz, Xepi, Bf-Rhodoled |
| Boehringer Ingelheim Pharmaceuticals, INC. | $106.80 | 2023-2025 | Spevigo, Cyltezo |
| Leo Pharma INC. | $92.59 | 2023-2025 | Adbry |
| Pfizer INC. | $80.50 | 2021-2023 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $69.38 | 2022-2025 | Sotyktu |
| Arcutis Biotherapeutics, INC. | $54.51 | 2023-2025 | Zoryve |
| Nobelpharma America, LLC | $36.66 | 2023 | |
| Dermavant Sciences, INC. | $31.03 | 2023 | Vtama |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $23.48 | 2025 | Cabtreo, Jublia, Siliq |
| Kyowa Kirin, INC. | $21.14 | 2024 | Poteligeo |
| Galderma Laboratories, L.P. | $18.99 | 2025 | Nemluvio |
| Verrica Pharmaceuticals INC. | $16.43 | 2024 | Ycanth |
| Smith+Nephew, INC. | $16.34 | 2024 | Grafix Pl, Stravix |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tiffany Replogle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.